



**basilea**

**David Veitch, CEO**



# Disclaimer and forward-looking statements

This communication including the accompanying oral presentation contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers” and words of similar import or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on current expectations and belief of company management, which are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Company’s products by the market in case they obtained regulatory approval, competition from other biotechnology, chemical and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, early stage of sales and marketing structure and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law.


# Basilea at a glance

- Revenue-generating, commercial-stage biotech company with solid cash position (HY2019 ~CHF 178mn)
- Focused in the areas of oncology, hospital antifungals and hospital antibiotics
- Two marketed anti-infective brands (Cresemba® and Zevtera®) and three oncology drug candidates in development
- Potential for sustainable growth and value generation based on increasing revenues and selective investments into internal and external innovation
- Founded in 2000
- Listed on the SIX Swiss Stock Exchange (SIX: BSLN)
- Based in life sciences hub Basel (Switzerland)





# Potential for sustainable growth and value creation based on commercialized products and innovative pipeline



\* pre-clinical reformulation activities ongoing.

Tecentriq® is a registered trademark of Hoffmann-La Roche Ltd.

# Established strong partnerships to fully exploit commercial potential of Cresemba<sup>®</sup> and Zevtera<sup>®</sup>

## License partners

- **Pfizer**  
Europe (ex. Nordics), China, Asia-Pacific, Russia, Turkey and Israel (*Cresemba*)
- **Astellas**  
U.S. (*Cresemba*)
- **Asahi Kasei Pharma**  
Japan (*Cresemba*)
- **CR Gosun**  
China (*Zevtera*)

## Distribution partners

- **Correvio**  
Europe (ex. Nordics), Israel (*Zevtera*)
- **Hikma**  
MENA region (*Cresemba and Zevtera*)
- **Grupo Biotoscana**  
LatAm (*Cresemba and Zevtera*)
- **Unimedic**  
Nordics (*Cresemba and Zevtera*)
- **Avir**  
Canada (*Cresemba and Zevtera*)

# >100 countries covered by partnerships

## Ongoing participation



- Double-digit royalties on sales by license partners
- Participation in sales of distribution partners through transfer price
- ~USD 245mn upfront and milestone payments received
- USD 1.1bn in potential milestones remaining



Antifungal

# Cresemba® (isavuconazole)


Invasive mold infections



# Invasive fungal infections — An area of continued high unmet medical need

- Severe, potentially life-threatening infections mainly affecting immunocompromised patients
- An important cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens
- Rising number of immunocompromised patients (cancer and transplantations) driving therapeutic demand
- Mucorales infections on the rise – doubled from 2000 to 2013
- Limitations of current therapies (spectrum of activity, toxicity, effective plasma levels) drive the need for new agents

## Mortality rates for invasive fungal infections\*\*




\*\*Kullberg/Arendrup *N Engl J Med* 2015, Baddley *Clin Infect Dis* 2010, Roden *Clin Infect Dis* 2005, Greenberg *Curr Opin Infect Dis* 2004



# Cresemba<sup>®</sup> continues strong sales uptake


Approx. USD 170mn in-market sales in MAT Q1 2019



LCD: USD corrected for currency fluctuations; MAT: Moving annual total; Source: IQVIA, March 2019

# Sales of best-in-class antifungals\* by product

USD 3bn sales (MAT Q1 2019)



\* Best-in-class antifungals: isavuconazole, posaconazole, voriconazole, AmBisome, anidulafungin, caspofungin, micafungin

MAT: Moving annual total; Sales figures in USD, corrected for currency fluctuations;  
Source: IQVIA, March 2019

# Cresemba® — Differentiated by spectrum, safety and tolerability

- Broad spectrum of activity against molds, including emerging molds (mucorales)
- Consistent plasma levels
- Statistically fewer drug-related adverse events and treatment-emergent adverse events (liver, skin, eye) in invasive aspergillosis patients vs. voriconazole in SECURE phase 3 study
- Can be administered in patients with renal impairment
- Manageable drug-drug interaction profile
- Once daily maintenance dose, i.v./oral treatment
- ECIL-6 guideline: Cresemba recommended for the first-line treatment of invasive aspergillosis in leukemia and hematopoietic stem cell transplant patients. ECIL states that isavuconazole is as effective as voriconazole with a better safety profile.



# Cresemba® — Marketed in North America, Europe, Israel and selected Latin American countries

- Marketed in major European countries by Pfizer
  - USD 5mn sales milestone triggered in Q1 2019
- Marketed in the U.S. by Astellas
  - Astellas reported H1 2019 sales of USD 67mn (+24% Y-o-Y)
  - CHF 10mn sales milestone triggered in Q4 2018
- Anticipated to double the number of launched countries in 2019
- Exclusivity through 2027 in the U.S. and potential pediatric exclusivity extension to 2027 (from 2025) in the EU



Antibacterial

# Zevtera<sup>®</sup>/Mabelio<sup>®</sup> (ceftobiprole)

Hospital\*-and community-acquired pneumonia



\* HAP (excluding VAP)



# Zevtera®/Mabelio® — A fast-acting hospital antibiotic with activity against a broad range of bacteria

- Broad-spectrum anti-MRSA cephalosporin (including Gram-negative bacteria)
- Rapid bactericidal activity
- Potential to replace antibiotic combinations
- Early improvement in HAP, particularly in patients with MRSA, and CAP, including high-risk patients
- Cephalosporin class safety profile
- Marketed in selected countries in Europe, Latin America and the MENA-region as well in Canada


Approved in major European countries & several non-European countries for both hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), and community-acquired pneumonia (CAP). Not approved in the U.S.






# Anti-MRSA hospital antibiotics market — A USD 3.1bn market with the U.S. being the most important region


Global anti-MRSA hospital antibiotics sales\*  
USD 3.1bn (MAT Q1 2019)



Daptomycin sales by region 2015 (before LOE)



Ceftaroline sales by region (MAT Q1 2019)



\* Vancomycin, linezolid, teicoplanin, daptomycin, tigecycline, telavancin, ceftaroline, dalbavancin, oritavancin and tedizolid  
MRSA: Methicillin-resistant Staphylococcus aureus; LOE: Loss of exclusivity; ROW: Rest of world  
MAT: Moving annual total; Sales figures in USD, corrected for currency fluctuations; Source: IQVIA, March 2019

# Two phase 3 studies are required to gain U.S. regulatory approval for ceftobiprole

- Two cross-supportive studies under FDA Special Protocol Assessment (SPA)
- Acute Bacterial Skin and Skin Structure Infections (successfully completed)<sup>1</sup>



- *Staphylococcus aureus* bacteremia (ongoing, anticipated to report topline results in H2 2021)<sup>2</sup>



<sup>1</sup> NCT03137173

<sup>2</sup> NCT03138733

- Partial funding of phase 3 program by BARDA (up to USD 128mn, ~70% of total program costs)



- Qualified Infectious Disease Product (QIDP) designation extends U.S. market exclusivity to 10 years from approval


# Ceftobiprole — positive topline phase 3 results reported in ABSSSI

Key topline study<sup>1</sup> results showing non-inferiority of ceftobiprole to vancomycin plus aztreonam for the primary and secondary endpoints



<sup>1</sup> NCT03137173  
ABSSSI: Acute bacterial skin and skin structure infections

## Early clinical response at 48–72h after start of treatment (ITT population)



ITT: intent-to-treat  
Pre-defined limit of non-inferiority = lower limit of 95 % CI for difference > -10 %



# Ceftobiprole — positive topline phase 3 results reported in ABSSSI


Key topline study<sup>1</sup> results showing non-inferiority of ceftobiprole to vancomycin plus aztreonam for the primary and secondary endpoints



<sup>1</sup> NCT03137173  
ABSSSI: Acute bacterial skin and skin structure infections

## Investigator-assessed clinical success at test-of-cure (TOC) 15-22 days after randomization (ITT, CE populations)

Patients with clinical success at the TOC visit (%)



CE: clinically evaluable; ITT: intent-to-treat


Oncology

# Derazantinib

FGFR-driven tumors

# Derazantinib — Targeting FGFR-driven tumors as single agent and in combination with immunotherapy

- Small molecule, oral inhibitor of Fibroblast Growth Factor Receptor (FGFR) family of kinases, in-licensed from ArQule
  - panFGFR kinase inhibitor with strongest activity against FGFR1, 2 and 3
- Development strategy focused on achieving differentiation by leveraging unique properties of derazantinib
  - Kinase inhibition profile: exploring therapeutic potential of additional targets of derazantinib such as CSF1R (Colony-stimulating Factor 1 Receptor) kinase
  - Safety profile: exploring relevance for potential combination therapies
- Two clinical studies ongoing
  - Urothelial cancer phase 1/2 study: Monotherapy and in combination with immune-checkpoint inhibitor atezolizumab (Tecentriq®)
  - Intrahepatic cholangiocarcinoma (iCCA) registrational phase 2 study: Monotherapy in FGFR2 gene fusions and other FGFR2 genetic aberrations



Sources: Helsten et al., Clin Cancer Res 2016 (22), 257-267; FGFR2 fusions in iCCA: Graham et al. Hum Pathol 2014 (45), 1630-1638; Jain et al. JCO Precis Oncol 2018 (2) 1-12



# FGFR-inhibitors show differences in kinase-inhibition profiles

FGFR-inhibitor compound (Sponsor)	Parameter	FGFR1	FGFR2	FGFR3	FGFR4	CSF1R (FMS)
<b>Derazantinib</b> (Basilea)	Ratio to FGFR2 activity	4	1	4	77	3
<b>Pemigatinib</b> (Incyte)	Ratio to FGFR2 activity	3	1	4	39	231
<b>Erdafitinib</b> (Janssen)	Ratio to FGFR2 activity	2	1	2	13	95
<b>Rogaratinib</b> (Bayer)	Ratio to FGFR2 activity	5	1	6	18	116
<b>Infigratinib</b> (QED)	Ratio to FGFR2 activity	2	1	2	47	86
<b>Futibatinib</b> (Taiho)	Ratio to FGFR2 activity	2	1	2	18	NA


Source: Basilea data on file

# Potential therapeutic relevance of CSF1R-inhibition

- Derazantinib is active in inhibiting FGFR kinases and CSF1R (Colony-stimulating factor-1 receptor)
- CSF1R-inhibition may reprogram immunosuppressive tumor-infiltrating macrophages, restore T-cell activity and thereby improve the susceptibility to PD1/PD-L1 inhibitors<sup>1</sup>
- Derazantinib may address several oncogenic mechanisms at the same time, i.e. inhibiting FGFR and making the tumor more susceptible to immunotherapy
- Basilea entered into a clinical supply agreement with Roche to study a combination of derazantinib and Roche's PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in patients with urothelial cancer

Sources:

<sup>1</sup> X. Zheng et al. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. *Oncotarget*. 2017;8(29):48436-48452



<sup>2</sup> Graph adapted from: A. Ghasemzadeh et al. New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. *Clin Cancer Res*. 2016;22(4):793-801

# FGFR-inhibitors show differences in safety profiles

	Cholangiocarcinoma				Urothelial cancer	
	DZB <sup>1</sup> (N=29)	INF <sup>2</sup> (N=71)	FUT <sup>3</sup> (N=45)	PEM <sup>4</sup> (N=89)	PEM <sup>5</sup> (N=108)	ERD <sup>6*</sup> (N=99)
Dosing regimen	300mg QD	125mg Q4W QD for 3w	16 mg, 20 mg or 24 mg QD	13.5mg Q3W QD for 2w	13.5mg Q3W QD for 2w	8 mg QD (titr. to 9mg)
Most frequent AEs	Phosphorus↑ Dry mouth Nausea	Phosphorus↑ Fatigue Stomatitis	Phosphorus↑ Constipation AST↑	Phosphorus↑ Alopecia Diarrhoea	Diarrhoea Alopecia Constipation	Phosphorus↑ Stomatitis Dry mouth
Blood phosphorus↑†	76%	73%	80%	61%	31%	73%
Fatigue† [G3]	41% [3%]	49% [4%]	NR	36% [4%]	32% [6%]	≥21% [≥2%]
Alopecia†	28%	38%	NR	37%	NR	≥27%
Dry eye/xerophthalmia†	21%	32%	NR	20%	NR	≥19%
Central serous retinopathy	0%	NR	NR	NR	NR	21%
ALT ↑	31%	NR	31%	NR	NR	41% <sup>7</sup>
Hand-foot syndrome/PPE	0%	27%	22%	NR	NR	≥22%
Nail events (drug-related)	<5%	NR	NR	NR	NR	52%
Stomatitis	7%	45%	22%	30%	34%	≥55%

Sources: <sup>1</sup> Mazzaferro et al., Br J Cancer 2018 and Basilea data on file; <sup>2</sup> Javle et al., ESMO 2018; <sup>3</sup> Meric-Bernstam et al, ESMO WC GI Cancer, 2018;

<sup>4</sup> Hollebecque, et al., ESMO 2018; <sup>5</sup> Necchi, et al., ESMO 2018; <sup>6</sup> Siefker-Radtke et al., ASCO 2018; <sup>7</sup> Balversa™ U.S. prescribing information (April 2019) based on reported laboratory abnormalities N=86 patients, regardless of causality.

Abbreviations: DZB: derazantinib, INF: infigratinib (BJG398), FUT: futibatinib (TAS-120), PEM: pemigatinib (INCB54828), ERD: erdafitinib;

PPES: Palmar-plantar erythrodysesthesia; NR: not reported; QD: daily; Q3W/Q4W: every 3/4 weeks; w: weeks.

\* Drug-related events reported only; † assumed FGFR inhibitor class-effect

# Derazantinib — Multi-cohort phase 1/2 study in advanced urothelial cancer (FIDES-02)<sup>1</sup>

- Derazantinib as single agent and in combination with atezolizumab (Tecentriq®) in patients with advanced urothelial cancer testing positive for mutations or fusions of FGFR1, FGFR2 or FGFR3 genes
- The subgroup of patients with low PD-L1 expression have limited clinical benefit from the treatment with PD1/PD-L1 inhibitors. This subgroup, however, shows frequent FGFR genomic abnormalities (mainly FGFR3 fusions)
- Derazantinib combined with PD1/PD-L1 inhibitors may provide benefits related to multiple mechanisms (FGFR-inhibition, macrophage modulation, enhanced response to immunotherapy), in particular in the low PD-L1 expression subgroup
- Across a total of four sub-studies, FIDES-02 potentially can enroll up to approximately 300 patients
- Patient cohorts in various treatment settings, including:
  - Post-chemotherapy/immunotherapy recurrence (second-and post second-line)
  - First-line platinum-ineligible
  - Resistance to prior FGFR-inhibitor treatment
- Study conducted in multiple centers in Asia-Pacific, Europe and North America
- Clinical supply agreement with Roche for the immune-checkpoint inhibitor atezolizumab (Tecentriq®)


<sup>1</sup> NCT04045613



# Derazantinib — Established proof-of-concept in iCCA in phase 1/2a study

- Subgroup analysis of 29 patients with FGFR2-fusion positive iCCA:
  - Objective response rate of 21%
  - In 72% of patients, tumor response or disease stabilization for  $\geq 16$  weeks was achieved\*
- Compares favorably to Standard-of-Care (SoC) chemotherapy (cross-trial comparison)
  - Objective Response Rate (ORR) 21% for derazantinib<sup>1</sup> versus  $<10\%$  for SoC<sup>2, 3</sup>
  - Progression-Free Survival (PFS) approx. 6 months<sup>1</sup> versus 3 months for SoC<sup>2, 3</sup>
- Manageable safety profile<sup>1, 4</sup>

<sup>1</sup> V. Mazzaferro et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. *British Journal of Cancer* 2018 <sup>2</sup> A. Lamarca et al. Second-line chemotherapy in advanced biliary cancer: a systematic review. *Annals of Oncology* 2014 (25), 2328-2338; <sup>3</sup> L. Fornaro et al. Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. *Journal of Experimental & Clinical Cancer Research* 2015 (34), 156 <sup>4</sup> K. P. Papadopoulos et al. A phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumors. *British Journal of Cancer* 2017, 1-8



Sources: Mazzaferro et al. *British Journal of Cancer* 2018;  
\* Mazzaferro et al. *J Clin Oncol* 2017;35 suppl: abstract 4017

# Derazantinib — Potential for accelerated U.S. approval based on registrational phase 2 study in iCCA (FIDES-01)<sup>1</sup>

**Cohort 1:** Patients with FGFR2 gene-fusion expressing iCCA (2nd line)

- Encouraging interim results reported early 2019, consistent with the earlier phase 1/2 data
- 21% ORR with six confirmed partial responses from 29 evaluable patients, 83% disease control rate
- Safety profile and tolerability of continuous dosing schedule confirmed
- Topline data expected mid-2020

**Cohort 2:** Patients with FGFR2 gene mutations or amplifications

- Started in June 2019
- Assessing the activity of derazantinib in a broader range of FGFR2-driven tumors
- Define the full therapeutic potential of derazantinib in iCCA with potential for differentiation
- Interim data expected H2 2020

<sup>1</sup> NCT03230318

Oncology


# BAL101553

Glioblastoma and ovarian cancer



# BAL101553 — Novel tumor checkpoint controller crossing the blood-brain barrier

- Novel compound inducing tumor cell death through spindle assembly checkpoint activation
- Destabilizing the microtubule scaffold through a novel target-binding site
- Targeting diverse tumor types resistant to standard therapeutic approaches
- Crosses the blood-brain barrier with potent activity in brain tumor models alone and in combination
- Flexible dosing potential, including daily oral dosing
- Comprehensive biomarker program to optimize patient and tumor selection




\* BAL101553 is a prodrug of BAL27862

Proprietary information of Basilea Pharmaceutica International Ltd. – not for distribution



# BAL101553 — Three ongoing clinical studies

- Phase 2a expansion (weekly 48-hour i.v.) in patients with recurrent glioblastoma (GBM) or platinum-resistant ovarian cancer<sup>1</sup>
  - Anticipated to complete around year-end 2019
- Phase 1 dose escalation (daily oral) in patients with recurrent glioblastoma<sup>2</sup>
  - Completed patient enrolment in August 2019
- Phase 1 study (daily oral) in combination with radiotherapy in patients with newly diagnosed glioblastoma in collaboration with the Adult Brain Tumor Consortium (ABTC)<sup>3</sup>
  - Anticipated to complete patient enrolment mid-2020



<sup>1</sup> NCT02895360

<sup>2</sup> NCT02490800

<sup>3</sup> NCT03250299; the ABTC is funded by the U.S. National Cancer Institute (NCI)


# EB1 — A potential response-predictive clinical biomarker for BAL101553

- EB1 (plus-end binding protein)<sup>1</sup> is located on the microtubules and involved in microtubule dynamics
- Predictive of response to BAL101553 in mouse models<sup>1</sup>


<sup>1</sup> Berges et al. Eur. J. Cancer 2018, 103,E61-62

## Effect of BAL101553 on survival in mice with EB1-expressing or EB1 downregulated GBM

### EB1-expressing GBM




### EB1-downregulated GBM




# EB1 — A potential response-predictive clinical biomarker for BAL101553

- Strong EB1 staining was observed in a patient with an exceptional response to daily oral BAL101553 in the phase 1 dose-escalation study in recurrent GBM<sup>1</sup>
  - Patient ongoing for > 15 months
  - ~70% reduction in GBM tumor size
- Potential utility of EB1 to support a biomarker-driven clinical program is currently being assessed


## GBM tumor size reduction in an exceptional responder and EB1 staining of GBM tissue compared to non-responding patients




Baseline (May 2018)



Post Cycle 12 (April 2019)



Responder




Non-responder

<sup>1</sup> Lopez et al, JCO 2019;37:15 suppl:2025

Oncology

**BAL3833**

Melanoma and RAS-driven tumors






# BAL3833 — panRAF/SRC kinase inhibitor

- In-licensed novel, oral, small molecule drug from consortium including the Wellcome Trust & Institute of Cancer Research (ICR)
- Resistance-reversal activity in BRAF/MEK inhibitor- and immunotherapy-resistant melanoma models
- Potential in diverse non-melanoma tumor types:
  - RAS-driven tumors
  - Expanded biomarker program to aid tumor selection
- Phase 1 dose-escalation study completed<sup>1</sup>
  - Broad dose range investigated, maximum tolerated dose (MTD) was not defined
  - Current formulation not continued based on pharmacokinetic profile
  - Conducting pre-clinical activities to explore alternative formulations


<sup>1</sup> NCT02437227





# Financials


# Financial summary H1 2019 and H1 2018



Note: Consolidated figures in conformity with U.S. GAAP; rounding applied consistently

# Revenue H1 2019 versus H1 2018


in CHF mn





# Cost and operating expenses H1 2019 versus H1 2018


in CHF mn



# Financial guidance 2019

In CHF mn	FY 2019 guidance	FY 2018 actuals	Y-o-Y change
Total revenue	128 – 133	132.6	-3% to +0%
thereof: Contributions Cresemba & Zevtera	105 – 110	82.0	+28% to +34%
Operating loss	22 – 27	24.1	-9% to +12%
Net operating cash consumption	60 – 65	79.2	-24% to -18%

Strong increase in Cresemba & Zevtera revenue contributions Y-o-Y, CHF mn



# Focus 2019 and beyond

**Cresemba® & Zevtera®/Mabelio® Increasing cash-generating revenues**  
**By the end of 2021, Cresemba to be on the market in >60 countries**

	H1 2019	H2 2019	H1 2020	H2 2020
<b>Ceftobiprole</b>		✓ Positive topline results from phase 3 ABSSSI study		
<b>Derazantinib</b>	✓ Positive interim results of phase 2 registrational study in iCCA FGFR2 fusions		Complete patient enrolment in phase 2 registrational study in iCCA FGFR2 fusions	Topline results from phase 2 registrational study in iCCA FGFR2 fusions
	✓ Extend ongoing phase 2 iCCA study in other FGFR gene aberrations			Interim data from iCCA in other FGFR gene aberrations
	✓ Clinical supply agreement with Roche in urothelial cancer	✓ Start phase 1/2 study in urothelial cancer		Interim data from first cohort(s) in urothelial cancer
<b>BAL101553</b>		✓ Complete patient enrolment in phase 1 study arm for recurrent glioblastoma (oral)	Full results from phase 1 study arm for recurrent glioblastoma (oral)	
		Complete phase 2a study in ovarian cancer and glioblastoma (48-hr. i.v.)		
				Complete patient enrolment in phase 1 study in newly diagnosed glioblastoma (oral)



© Basilea Pharmaceutica International Ltd. October 2019. All rights reserved.  
Grenzacherstrasse 487 — PO Box — 4005 Basel — Switzerland  
[investor\\_relations@basilea.com](mailto:investor_relations@basilea.com) — [www.basilea.com](http://www.basilea.com)